Buradasınız

FELTY SENDROMU: GRANÜLOSİT MAKROFAJ KOLONİ UYARICI FAKTÖR TEDAVİSİYLE BAŞARILI REMİSYON İNDÜKSİYONU VE SÜRDÜRME TEDAVİSİ

Journal Name:

Publication Year:

Abstract (2. Language): 
Felty's syndrome: Sııcesfııl remission indıtction and maintenance therapy witlı grcmıdocyte macrophage colony stimulating factor. Felty's syndrome (FS) is a dinieal piclııre clnıractori-zed vvith splenomegaly, leucopenia and recurrent infections in patients with rheumatoid arthri-tis (RA). FS was accepted as a rare and potentially fatal extraaıticular manifestation of RA. Herein, we presented a patient with FS who was admitted with splenomegaly, leucopenia and septicemia in addition to chronic polyarthritis. Although the articular symptoms were control-led by antibiotherapy and high dose corticosteroid treatment, leucopenia sustained. High dose corticosteroids, hydroxychloroquin, methotrexate and cyclosporin-A were tried during the fol-low-up which were succesfull in treating articular symptoms, but not leucopenia. Cyclic G-CSF treatment was started as 30 MÜ/d at three times v/eekly and after the improvement of leu-cocyte count, splenectomy was performed. Leucocyte count was not returned to normal levels after splenectomy and cyclic G-CSF treatment was restarted. The patient has been stili in remission for 8 months with G-CSF treatment. G-CSF treatment seems to be an effective and safe option for both remission induction and maintenance therapy in FS.
Abstract (Original Language): 
Felty sendromu (FS), romatoid artritli (RA) hastalarda görülebilen ve splenomegali, lökopeni ve tekrarlayan infeksiyon bulgularıyla seyreden bir klinik tablodur. Burada, kronik poliartrit ile birlikte, splenomegali, lökopeni ve sepsis tablosuyla başvuran FS'li bir hasta sunuldu. Hastalığın başlangıcında antibiyoterapi ve granülosit koloni uyarıcı faktör (G-CSF) tedavisi ile lökopeni ve sepsis tablosu kontrol altına alınabildi. Ancak, takibi süresince farklı zamanlarda uygulanan yüksek doz kortikosteroid, hidroksiklorokin, metotreksat ve siklosporin-A tedavileri ile eklem bulguları düzelirken lökopeni sebat etti. Haftada Uç gün olmak üzere 30 MÜ/gün dozunda "siklik" G-CSF tedavisi başlanan ve lökopenisi düzelen hastaya splenektomi uygulandı. Splenektomi sonrası ikinci ayda lökopeninin nüksetmesi üzerine, yeniden siklik G-CSF uygulamasına geçildi. Hasta halen takibinin 8. ayında remisyonda izlenmektedir. FS'de G-CSF tedavisi gerek remisyon indüksiyonu gerekse sürdürme tedavisinde etkili ve güvenilir bir tedavi seçeneği olarak görünmektedir.
279-282

REFERENCES

References: 

1. Turesson C, O'Fallon WM, Crovvson CS, Gabriel SE, Matteson EL. Occurrence of extraarticuler disease mani-festations is associated with excess mortality in a com-munity based cohort of patients with rheumatoid arthri-tis. J Rheumatol; 29:62 (2002).
2. Wollheim FA. Rheumatoid arthritis - the clinical picture. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology 2nd ed. New York: Oxford University Press,: 1352-1365 (1998).
Felty Sendromu: Granülosit Makrofaj Koloni Uyarıcı Faktör Tedavisiyle Başarılı Remisyon İndüksiyonu ve
Sürdürme Tedavisi
3. Breedveld FC, Fibbe WE, Cats A. Neutropenia and in-fections in Felty's syndrome. Br J Rheumatol; 27:19 (1988).
4. Hellmich B, Csernok E, de Haas M, von dem Borne A, Schatz H, Gross WL, Schnabel A. Low Fc(Receptor III and high granulocyte colony-stimulating factor serum le-vels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythemato-sus.AmJMed; 113:134 (2002).
5. Sibley IT, Haga M, Visram DA, Mitchell DM. The clini-cal course of Felty's syndrome compared to matched controls. J Rheumatol; 18:1163 (1991).
6. Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty's syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum; 32:194 (1989).
7. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty's syndrome. Med Hypotheses; 50:415 (1998).
8. Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felty's syndrome with leflunomide. J Rheumatol; 28:868 (2001).
9. Canvin JM, Dalal BI, Baragar F, Johnston JB. Cyclospo-rine for the treatment of granulocytopenia in Felty's syndrome. Am J Hematol; 36:219 (1991).
10. Dillon AM, Luthra HS, Conn DL. Parenteral gold therapy in the Felty's syndrome. Experience with 20 patients. Medicine 65:107 (1986).
11. Graham KE, Coodley GO. A prolonged use of granulocyte stimulating factor in Felty's syndrome. J Rheumatol; 22:174(1995).
12. Stanvvorth SJ, Bhavnani M, Chattopadhya C, Miller H, Svvinson DR. Treatment of Felty's syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). QJM; 91: 49 (1998).
13. Krishnasvvany G, odem C, Chi DS, Kalbfleisch J, Baker N, Smith JK. Resolution of neutropenia of Felty's stndro-me by longterm administration of recombinant granulocyte colony stimulating factor. J Rheumatol 1996;23(4):763-5
14. Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty's syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum ;29:82 (1999).
15. Moore RA, Brunner CM, Sandusky WR, et al: Felty's syndrome: Long-term follow-up after splenectomy. Ann InternMed ;75:381 (1971).
16. Laszlo J, Jones R, Silberman HR et al: Splenectomy for Felty's syndrome: Clinicopathological study of 27 patients. Arch Intern Med;138:597 (1978).
17. Coon WW. Felty's syndrome: When is splenectomy indi-cated ? Am J Surg;149:272 (1985).
18. Nakamura H, Ohishi A, Asano K, Hirose H, Hayakawa M, Iwai F, Kageyama T, Katsu M. Partial splenic embo-lization for Felty's syndrome: a 10-year followup. J Rheumatol; 21:1964 (1994).
19. Graham KE, Coodley GO. A prolonged use of granulocyte colony stimulating factor in Felty's syndrome. J Rheumatol; 22:174(1995).

Thank you for copying data from http://www.arastirmax.com